Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals PLC (CNTA) Stock Analysis

$40.500

+0.324 (+0.80%)At close

Loading chart…
High
40.560
Open
40.090
VWAP
40.35
Vol
11.33M
Mkt Cap
1.02B
Low
40.000
Amount
457.22M
EV/EBITDA, TTM
0.00

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Valuation Metrics

The current forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) is 0.00, compared to its 5-year average forward P/E of -6.10.

Forward P/E

Overvalued
5Y Average P/E
-6.10
Current P/E
0.00
Overvalued
-2.18
Undervalued
-10.03

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-4.75
Current EV/EBITDA
0.00
Overvalued
0.15
Undervalued
-9.64

Forward P/S

Fair
5Y Average P/S
270.93
Current P/S
313.33
Overvalued
1316.24
Undervalued
-774.38

Alphio AI Price Scenarios for CNTA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CNTA

$19.02

Scenario price

B

Base

Base · 50%CNTA

$16.76

Scenario price

B

Bear

Bear · 25%CNTA

$16.34

Scenario price

Whales holding CNTA

B

Braidwell LP

+ HoldingCNTA

+38.79%

3M Return

C

Commodore Capital LP

+ HoldingCNTA

+34.35%

3M Return

E

EcoR1 Capital, LLC

+ HoldingCNTA

+23.23%

3M Return

G

General Atlantic Service Company, L.P.

+ HoldingCNTA

+19.85%

3M Return

L

Logos Global Management, L.P.

+ HoldingCNTA

+17.53%

3M Return

F

Farallon Capital Management, L.L.C.

+ HoldingCNTA

+16.46%

3M Return

Events Timeline

2026-06-22 (ET)

16:30:00

Centessa to be Acquired by Eli Lilly for $38 per Share

2026-04-01 (ET)

07:40:00

LifeSci Capital Downgrades Centessa to Market Perform After Eli Lilly Acquisition

2026-03-31 (ET)

16:30:00

Dow Jones Index Rises 2.49% to 46,341.51

13:20:00

Alkermes Shares Rise 15% Following M&A Activity

Show More Events

News

Show More News

CNTA FAQ — answered by Alphio AI

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started